• Itraconazole 100 mg/200mg
  • Dosage Form: CAPSULES
  • Pack Type: STRIP
  • Pack Size: 1*10/1*4*10
  • Division: Unimax

Capitra 100/200


CAPITRA 100: Each hard gelatin capusle contains itraconazole 100mg

CAPITRA 200: Each hard gelatin capusle contains itraconazole 200mg.

Clinical Pharmacology:

Itraconazole is a  triazole antifungal drug which  acts by inhibiting the fungal cytochrome P-450 dependent enzyme lanosterol 14-α-demethylase. When this enzyme is inhibited, it blocks the conversion of lanosterol to ergosterol, a vital component of fungal cell membrane and thus disrupts fungal cell membrane synthesis.


Capitra is an antifungal agent used for the treatment of various fungal infections in immunocompromised and non-immunocompromised patients. It is indicated in the treatment of fungal infections like pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, onychomycosis, candidiasis, Tinea pedis, Tinea cruris and Tinea corporis.

Oropharyngeal candidiasis

Adult:  100 mg once daily for 15 days. Patients with AIDS or other immunocompromised (e.g. neutropenic) patients: 200 mg once daily for 15 days.

Systemic candidiasis

Adult:  100-200 mg once daily for 3 weeks to 7 months; increase to 200 mg bid in case of invasive or disseminated disease.

Tinea manuum, Tinea pedis

Adult: 100 mg once daily for 30 days. As pulse treatment: 200 mg bid for 7 days.

Cryptococcal meningitis

Adult:  200 mg bid for 2 months to 1 year.


Adult: For cases caused by dermatophytes and/or yeasts: 200 mg once daily for 3 months. As pulse treatment: 200 mg bid for 7 days, repeated once for fingernails or twice for toenails after drug-free intervals of 21 days.

Pityriasis versicolor

Adult:  100 mg bid or 200 mg once daily for 5-7 days.

Non-meningeal cryptococcosis

Adult:  200 mg once daily for 2 months to 1 year.

Vulvovaginal candidiasis

Adult:  200 mg bid for 1 day or 200 mg once daily for 3 days.


Adult: 200 mg once daily; may increase in increments of 100 mg to a Max of 400 mg daily, if there is no obvious improvement, or there is evidence of progressive fungal disease. Doses above 200 mg daily should be given in two divided doses. Treatment duration: 8 months. Maintenance therapy in AIDS patients: 200 mg 1-2 times daily until immune recovery.


Adult: 200 mg once daily for 2-5 months; increase to 200 mg bid in case of invasive or disseminated disease.

Tinea corporis, Tinea cruris

Adult: 100 mg once daily for 15 days or 200 mg once daily for 7 days.

Primary prophylaxis of infection in AIDS patients, Primary prophylaxis of infection in neutropenic patients, Secondary prophylaxis of infection in AIDS patients, Secondary prophylaxis of infection in neutropenic patients

Adult:  200 mg once daily; may increase to 200 mg bid if necessary.


Adult: 100 mg once daily to 200 mg bid for 6 months.

Absorption of itraconazole capsules may be decreased by certain antacids such as  Al hydroxide, H2-receptor antagonists, PPIs.

Plasma concentrations may be decreased by rifampicin, rifabutin, isoniazid, carbamazepine, phenytoin, phenobarbital, nevirapine, efavirenz.

Plasma concentrations may be increased by ciprofloxacin, clarithromycin, erythromycin, indinavir, ritonavir.

May increase the plasma concentrations of tamsulosin, certain opioid analgesics (e.g. alfentanil, sufentanil, buprenorphine, fentanyl, oxycodone), digoxin, certain anticoagulants (e.g. rivaroxaban, cilostazol, coumarins, dabigatran), repaglinide, saxagliptin, praziquantel, certain antihistamines (e.g. bilastine, ebastine), certain antineoplastics (e.g. docetaxel, vinca alkaloids, , imatinib), certain antipsychotics, anxiolytics and hypnotics (e.g. risperidone, alprazolam, buspirone, quetiapine, aripiprazole, haloperidol, midazolam IV), verapamil,  aliskiren, bosentan, , aprepitant, certain corticosteroids (e.g. budesonide, fluticasone, methylprednisolone, ciclesonide), salmeterol, certain immunosuppressants (e.g. ciclosporin, tacrolimus), certain urological drugs (e.g. tadalafil, sildenafil, darifenacin), tolvaptan, artemether and lumefantrine, atorvastatin.

Increased risk of QT prolongation and ventricular tachyarrhythmia (including torsades de pointes) with disopyramide, quinidine, methadone, levacetylmethadol, astemizole, mizolastine, terfenadine, halofantrine, cisapride, domperidone.

Side effects may include any of the following: headache, dizziness, stomach pain, nausea, vomiting, diarrhoea, constipation, indigestion, chest pain, chills, fever, tiredness, confusion, joint or muscle pain
Some side effects may need immediate medical help. Alert your doctor quickly if you experience any of the following:
  • signs and symptoms of severe allergic reactions e.g. rashes, breathlessness, swelling of the face, eyes or mouth
  • signs and symptoms of heart failure e.g. shortness of breath, swelling of your feet, ankles or legs, sudden weight gain, unusual tiredness, fast heartbeat, waking up with shortness of breath at night
  • signs and symptoms of liver impairment e.g. yellowing of the skin or eyes, abdominal pain, dark coloured urine, tiredness, swelling in the legs and ankles
  • tingling sensation, weakness or numbness in the hands or feet
  • sudden temporary or permanent hearing loss
Inform your doctor if any of these side effects do not go away or are severe, or if you experience other side effects.

Warnings and precautions

  • Cases of CHF, peripheral edema, and pulmonary edema have been reported with itraconazole administration among patients being treated for onychomycosis and/or systemic fungal infections. 
  • Cardiac Dysrhythmias Life-threatening cardiac dysrhythmias and/or sudden death have occurred in patients using cisapride, pimozide, levacetylmethadol (levomethadyl), methadone, or quinidine concomitantly with itraconazole and/or other CYP3A4 inhibitors. Concomitant administration of these drugs with itraconazole is contraindicated.
  • Itraconazole should not be administered in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. Itraconazole has been shown to have a negative inotropic effect.  For patients with risk factors for congestive heart failure, physicians should carefully review the risks and benefits of itraconazole therapy. 
  • In patients with elevated or abnormal liver enzymes or active liver disease, or who have experienced liver toxicity with other drugs, treatment with itraconazole is not recommended. Itraconazole has been associated with rare cases of serious hepatotoxicity, including liver failure and death. If clinical signs or symptoms develop that are consistent with hepatotoxicity, treatment should be discontinued immediately and liver function testing performed.
  • Calcium channel blockers can have negative inotropic effects which may be additive to those of itraconazole. In addition, itraconazole can inhibit the metabolism of calcium channel blockers. Therefore, caution should be used when coadministering itraconazole and calcium channel blockers due to an increased risk of CHF. 



Teratogenic effects; Pregnancy Category C

There are no adequate and well-controlled clinical trials in the pregnant women with itraconazole. However, cases of congenital abnormalities have been reported with itraconazole drug products in post-marketing reports. Therefore, it should not be administered to pregnant women, women planning pregnancy, or women of child bearing potential. Itraconazole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

Itraconazole is excreted in human milk; therefore, the expected benefits of itraconazole therapy for the mother should be weighed against the potential risk from exposure of itraconazole to the infant.